Analytical Data
-
Gene name
MYH16
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H6N6
-
Expression Region
Val209~Thr469
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYH16 is a gene that encodes a myosin heavy chain protein, which plays a critical role in muscle contraction and is primarily expressed in skeletal muscle tissue. Research into MYH16 has gained attention due to its potential implications in various muscular and genetic disorders. Notably, mutations in the MYH16 gene have been associated with congenital myopathies, which can result in severe muscle weakness and developmental delays. The study of MYH16 recombinant proteins is particularly important for understanding the functional properties of the myosin heavy chain family and elucidating the molecular mechanisms underlying muscle contraction. Additionally, recombinant MYH16 proteins can serve as valuable tools for drug discovery, providing insights into therapeutic targets for muscle-related diseases. Recent advancements in genetic engineering techniques have facilitated the production of these recombinant proteins, allowing researchers to investigate their structural and functional characteristics in vitro. This research not only enhances our understanding of muscle physiology but also paves the way for potential clinical applications, including gene therapy and regenerative medicine. Overall, MYH16 represents a significant focus within muscle biology, highlighting its importance in both basic research and translational applications in the field of muscle pathologies.
